Experimental cocktail aims to boost immune attack on childhood brain tumors
Disease control
Recruiting now
This early-phase trial tests whether adding ibrutinib to an existing immunotherapy and chemotherapy regimen can safely improve treatment for children and young adults (ages 6–25) with brain cancers like medulloblastoma or glioblastoma that have come back or not responded to stand…
Phase: PHASE1 • Sponsor: Theodore S. Johnson • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC